Teva Pharmaceuticals (TEVA)

• Market cap: $17.3B
• 1 day: -2.65%
• 5 days: -5.40%
• 1 month: -8.38%
• 3 months: -32.44%
• 6 months: -16.32%
• Year to date: -29.20%
• 1 year: 6.87%
• 5 years: 77.20%
• 10 years: -75.88%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 35,686

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

107% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 45

81% more call options, than puts

Call options by funds: $727M | Put options by funds: $402M

30% more capital invested

Capital invested by funds: $11.3B [Q3] → $14.6B (+$3.38B) [Q4]

29% more funds holding in top 10

Funds holding in top 10: 28 [Q3] → 36 (+8) [Q4]

6% more funds holding

Funds holding: 534 [Q3] → 567 (+33) [Q4]

2.5% more ownership

Funds ownership: 56.17% [Q3] → 58.67% (+2.5%) [Q4]

1% more repeat investments, than reductions

Existing positions increased: 190 | Existing positions reduced: 188

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 33% upside
• Avg. target: $26 71% upside
• High target: $30 99% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Jason Gerberry 40% 1-year accuracy 8 / 20 met price target	33% upside $20	Buy Maintained	6 Mar 2025
UBS Ashwani Verma 22% 1-year accuracy 4 / 18 met price target	79% upside $27	Buy Maintained	30 Jan 2025
Barclays Balaji Prasad 30% 1-year accuracy 13 / 44 met price target	72% upside $26	Overweight Maintained	30 Jan 2025
Piper Sandler David Amsellem 55% 1-year accuracy 18 / 33 met price target	99% upside $30	Overweight Maintained	17 Jan 2025